Agenus Inc. buy tamam
Summary
This prediction ended on 07.04.16 with a price of €4.22. With a performance of -4.88%, the BUY prediction by tamam finished with a loss. tamam has 50% into this predictionAgenus is a biotechnology company focused on developing immunotherapies to treat cancer and other diseases. The company's product pipeline includes checkpoint inhibitors, which work by blocking proteins that help cancer cells evade detection by the immune system, as well as other immunotherapies designed to stimulate the body's immune response to tumors. Agenus has collaborations with large pharmaceutical companies including Merck, Incyte, and Gilead, and is actively working on bringing its products to market through clinical trials and regulatory approval. The company is listed on the NASDAQ stock exchange under the ticker symbol AGEN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Agenus Inc. | - | - | - | - |
| iShares Core DAX® | 2.821% | -1.953% | 15.071% | 11.862% |
| iShares Nasdaq 100 | 5.285% | -5.092% | 29.254% | 40.075% |
| iShares Nikkei 225® | 3.687% | -4.221% | 14.286% | 6.629% |
| iShares S&P 500 | 3.577% | -2.240% | 25.546% | 38.398% |
Comments by tamam for this prediction
In the thread Agenus Inc. diskutieren
The company has strong analyst support, a deep pipeline, is flush with cash,
and it has deep pocketed development partners.
There were myriad catalysts for the company's previous rise that are still in place, and Agenus has had another positive development that has been overlooked during the recent rout in biotech. When sentiment changes back into positive territory; investors will take note and bid up this promising biotech concern once again.
As such, Agenus is an extremely solid risk/reward play at current levels. STRONG SPECULATIVE BUY